Employees: 1,990
Size Guangdong Hybribio Biotech (300639.SZ) is a China Health Care company (Medical Specialties) with a market value of $511M, the 3650th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.18 on 18 Nov 2026.
Performance Over six months the shares fell 17.9%, against -17.4% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue fell 7.2% over the last twelve months (peer median +7.0%); the operating margin is 4.4% (peer median 2.2%).
Valuation It trades at 57.3× forward earnings against a peer median of 21.1× (most expensive of 9).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -13%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.3 points below its cost of capital (5.6% WACC).
Next results Next results expected around 9 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥642M | CN¥665M | CN¥812M | CN¥1.10B | CN¥5.58B |
| Revenue growth | — | -18% | -26% | -80% | — |
| Gross profit | CN¥353M | CN¥215M | CN¥296M | CN¥579M | CN¥3.76B |
| EBITDA | n/a | -CN¥16.2M | -CN¥615M | CN¥189M | CN¥2.61B |
| Net income | CN¥66.7M | -CN¥131M | -CN¥655M | CN¥140M | CN¥1.73B |
| Free cash flow | CN¥231M | CN¥251M | -CN¥69.6M | -CN¥58.1M | CN¥575M |
| Capital expenditure | CN¥147M | CN¥92.4M | CN¥148M | CN¥385M | CN¥734M |
| Total debt | CN¥178M | CN¥89.6M | CN¥87.5M | CN¥56.7M | CN¥139M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300639.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -17.2% | -4.6% | lowest of 21 |
| 6-month return | -17.9% | -17.4% | 11th highest of 21 |
| Distance from 52-week high | -48.6% | -40.8% | 5th lowest of 21 |
| Revenue growth (TTM) | -7.2% | +7.0% | 4th lowest of 21 |
| Operating margin | 4.4% | 2.2% | 9th highest of 21 |
| Forward P/E | 57.3× | 21.1× | most expensive of 9 |
| Growth the price implies (Req g, 7 yrs) | 0.4% | 8.7% | 2nd least demanding of 11 |
| Growth delivered (Del g) | -13.2% | -0.1% | 3rd lowest of 11 |
| Hurdle (Req g minus delivered) | +13.6 pp | +8.8 pp | 6th least demanding of 11 |
| ROIC minus cost of capital | -1.3 pp | -2.2 pp | 8th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 57.3× | 0.4% | -13.2% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 13.2× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | n/a | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | n/a | 30.8% | -18.6% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | n/a | 6.0% | -7.7% |
| Zhejiang Orient Gene Biotech 688298.SS | China | $500M | -27% | +18% | -60% | n/a | n/a | n/a |
| Nanjing Vishee Medical Technology 688580.SS | China | $499M | -43% | +7% | 24% | 19.7× | 20.1% | +4.2% |
| medmix MEDX.SW | Switzerland | $494M | +11% | -7% | 6% | 19.4× | 4.5% | +5.0% |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | n/a | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | n/a | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | n/a | n/a | n/a |
| Zhejiang Starry Pharmaceutical 603520.SS | China | $491M | -44% | +9% | 3% | 25.8× | n/a | n/a |
| Wuhan Easy Diagnosis Biomedicine 002932.SZ | China | $485M | -14% | -9% | -51% | n/a | n/a | n/a |
| Hangzhou Alltest Biotech 688606.SS | China | $484M | -20% | 0% | 13% | 6.9× | -6.5% | -4.3% |
| Medprin Regenerative Medical Technologies 301033.SZ | China | $482M | -14% | +23% | 31% | 22.4× | 4.3% | +24.4% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 23.5× | 10.2% | +6.5% |
| Guangdong Biolight Meditech 300246.SZ | China | $478M | -35% | +7% | -8% | n/a | 55.3% | -4.7% |
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | n/a | 15.0% | -19.8% |
| CellaVision CEVI.ST | Sweden | $477M | +64% | +2% | 23% | 32.6× | 7.1% | +10.0% |
| AngioDynamics ANGO | United States | $476M | -4% | +8% | -6% | n/a | n/a | n/a |